study endpoints in clinical research Archives

Launching a New Drug During a Pandemic? Successful Launches Included a Rapid Pivot to Social Media
Patient insights, Marketing

Launching a New Drug During a Pandemic? Successful Launches Included a Rapid Pivot to Social Media

Launching a New Drug During a Pandemic? Successful Launches Included a Rapid Pivot to Social Media By Paul Nash How has the pandemic affected pharmaceutical product launches? Experts say that social media and research have been the key factors for this year’s successful launches. In a webcast on the PharmaVoice Webcast Network, “The State of Product Launch During and Post COVID-19,” speakers Maya Desai, Director at Guidehouse; Lead Launch COE, Eduardo Schur, Partner and life sciences global practice lead, Guidehouse; and Justin Zamirowski, Chief Commercial Officer, Better Therapeutics, described key results from their studies into recent pharmaceutical [...]

How Has COVID-19 Impacted Patients with Rare Conditions?

How Has COVID-19 Impacted Patients with Rare Conditions? By Judy Chandler Over 600,000 Inspire members are affected by rare conditions. As a vital partner to 40 rare disease non-profit advocacy organizations, Inspire’s rare disease patient and caregiver members represent over 3,000 rare conditions. Serving as a common point across these diverse conditions, Inspire was uniquely positioned to learn how rare disease communities were being affected by COVID-19. First, we noticed a surge of COVID-19 posts across all of Inspire through the month of March. Inspire’s research team began by reviewing some of these member communications to identify [...]

Patients Are The Best Resource For Defining Study Endpoints

Patients Are The Best Resource For Defining Study Endpoints By Robert Gardner In September, the World Orphan Drug Congress USA Fall Webinar series opened with a program called: “Understanding the Novel Challenges in Rare Disease Development: Perspectives From Experts.” They took an audience poll, asking attendees to identify their “biggest challenge in rare disease studies” from five choices, including competition for patients; lack of understanding of disease progression; development of appropriate endpoints; lack of data; and global regulatory pathways. Almost half the respondents -- 46% -- chose “development of appropriate endpoints” as the biggest challenge in rare [...]